Literature DB >> 2921317

Relationship between whole plasma calcitonin levels, calcitonin secretory capacity, and plasma levels of estrone in healthy women and postmenopausal osteoporotics.

J Y Reginster1, R Deroisy, A Albert, D Denis, M P Lecart, J Collette, P Franchimont.   

Abstract

The exact role of calcitonin (CT) in the pathogenesis of postmenopausal osteoporosis remains unknown. Whole plasma calcitonin (iCT) basal levels, metabolic clearance rate (MCR), and production rate (PR) of CT were measured in 9 premenopausal and 16 postmenopausal women, including 11 osteoporotics (OP). Basal iCT levels were statistically lower in postmenopausal women than in the premenopausal group (P less than 0.01) and strongly correlated (r = 0.72; P less than 0.001) with estrone circulating levels (E1). MCR were similar in all groups. PR were similar in eugonadal women between 22 (mean +/- SD = 30.9 +/- 9.9 micrograms/d) and 37 yr (mean +/- SD = 25.5 +/- 11.1 micrograms/d) premenopausal women. In healthy postmenopausal women PR were reduced, but not significantly (mean +/- SD = 19.5 +/- 6.95 micrograms/d), whereas osteoporotic patients presented a highly significant reduction of CT PR (mean +/- SD = 9.8 +/- 4 micrograms/d) (P less than 0.01). Because there is a strong relationship between E1 and PR (r = 0.64; P less than 0.001), CT secretory capacity appears to be modulated by estrogen circulating levels. This modulation leads to a menopause-related decrease in iCT. In osteoporotics, an independent impairment of CT production drastically lowers PR and basal iCT levels. CT might be one of the determining factors in the pathogenesis of postmenopausal osteoporosis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2921317      PMCID: PMC303786          DOI: 10.1172/JCI113950

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  20 in total

1.  Immunochemical heterogeneity of calcitonin in plasma.

Authors:  L J Deftos; B A Roos; D Bronzert; J G Parthemore
Journal:  J Clin Endocrinol Metab       Date:  1975-03       Impact factor: 5.958

2.  Plasma calcitonin in normal man. Differences between men and women.

Authors:  H Heath; G W Sizemore
Journal:  J Clin Invest       Date:  1977-11       Impact factor: 14.808

3.  Effects of calcitonin on patients with Paget's disease, thyrotoxicosis, or hypercalcaemia.

Authors:  O L Bijvoet; J van der Sluys Veer; A P Jansen
Journal:  Lancet       Date:  1968-04-27       Impact factor: 79.321

4.  Multiple immunoreactive forms of calcitonin in human plasma.

Authors:  F R Singer; J F Habener
Journal:  Biochem Biophys Res Commun       Date:  1974-11-27       Impact factor: 3.575

5.  Human calcitonin radioimmunoassay in normal and pathological conditions.

Authors:  G Heynen; P Franchimont
Journal:  Eur J Clin Invest       Date:  1974-06       Impact factor: 4.686

6.  Mode of action of thyrocalcitonin.

Authors:  J L O'Riordan; G D Aurbach
Journal:  Endocrinology       Date:  1968-02       Impact factor: 4.736

7.  Thyrocalcitonin: inhibitor of bone resorption in tissue culture.

Authors:  J Friedman; L G Raisz
Journal:  Science       Date:  1965-12-10       Impact factor: 47.728

8.  Calcitonin secretion in postmenopausal osteoporosis.

Authors:  R D Tiegs; J J Body; H W Wahner; J Barta; B L Riggs; H Heath
Journal:  N Engl J Med       Date:  1985-04-25       Impact factor: 91.245

9.  1-Year controlled randomised trial of prevention of early postmenopausal bone loss by intranasal calcitonin.

Authors:  J Y Reginster; D Denis; A Albert; R Deroisy; M P Lecart; M A Fontaine; P Lambelin; P Franchimont
Journal:  Lancet       Date:  1987-12-26       Impact factor: 79.321

10.  Relative deficiency of plasma-calcitonin in normal women.

Authors:  C J Hillyard; J C Stevenson; I MacIntyre
Journal:  Lancet       Date:  1978-05-06       Impact factor: 79.321

View more
  17 in total

1.  Calcitonin and estrogens.

Authors:  D Agnusdei; R Civitelli; A Camporeale; C Gennari
Journal:  J Endocrinol Invest       Date:  1990-09       Impact factor: 4.256

2.  Circulating monomer-like calcitonin in osteoporotic patients.

Authors:  H Rong; M Sääf; O Tørring; U Sjöstedt; E Bucht
Journal:  Osteoporos Int       Date:  1996       Impact factor: 4.507

Review 3.  Minerals and osteoporosis.

Authors:  H Rico
Journal:  Osteoporos Int       Date:  1991-10       Impact factor: 4.507

Review 4.  Heterogeneity of osteoporotic syndromes and the response to calcitonin therapy.

Authors:  L V Avioli
Journal:  Calcif Tissue Int       Date:  1991       Impact factor: 4.333

Review 5.  Role of oestrogen in the development of osteoporosis.

Authors:  T C Hillard; J C Stevenson
Journal:  Calcif Tissue Int       Date:  1991       Impact factor: 4.333

6.  Does estrogen replacement therapy influence parathyroid hormone responsiveness to exogenous hypercalcemia in postmenopausal women?

Authors:  I Zofková; S Röjdmark; R L Kancheva
Journal:  J Endocrinol Invest       Date:  1993-05       Impact factor: 4.256

7.  Associations between body morphology and bone mineral density in premenopausal women.

Authors:  P Orozco; J M Nolla
Journal:  Eur J Epidemiol       Date:  1997-12       Impact factor: 8.082

8.  Breast cancer and osteoporosis - management of cancer treatment-induced bone loss in postmenopausal women with breast cancer.

Authors:  Matthias Kalder; Peyman Hadji
Journal:  Breast Care (Basel)       Date:  2014-10       Impact factor: 2.860

Review 9.  Intranasal salmon calcitonin. A review of its pharmacological properties and potential utility in metabolic bone disorders associated with aging.

Authors:  S P Clissold; A Fitton; P Chrisp
Journal:  Drugs Aging       Date:  1991 Sep-Oct       Impact factor: 3.923

10.  Estrogen receptors and biologic response in rat parathyroid tissue and C cells.

Authors:  T Naveh-Many; G Almogi; N Livni; J Silver
Journal:  J Clin Invest       Date:  1992-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.